The transfer of messenger RNA technology (abbr. mRNA) and the development of medicines based on mRNA for the Republic of Serbia represent a major step forward in the field of vaccinology at the global level. It is expected that the mRNA technology will gain an advantage in the prevention of infectious diseases, and there are high hopes that this technological platform, with minimal modifications, will also be used in the treatment of chronic non-infectious diseases.
The Institute of Virology, Vaccines, and Sera “Torlak” has been acknowledged by the World Health Organization to engage in the mRNA Technology Transfer Hub Program. This initiative, facilitated by Afrigen Biologics and Vaccines, a Medicines Patent Pool organization supported by the World Health Organization, aims at transferring mRNA technology and developing vaccines and medicines based on mRNA. In addition to the “Torlak” Institute, 14 other institutes from diverse countries will also have access to mRNA technology as part of this project. The involvement of various institutes, scientific institutions, and pharmaceutical companies creates opportunities for collaboration, knowledge exchange, joint projects, and production cooperation.
The primary goal of the mRNA technology transfer project is to facilitate the development of innovative medicines and vaccines in the Republic of Serbia. This initiative aims to ensure the availability of the latest generation therapies to the population.
The project envisions that the employees of the “Torlak” Institute participating in the mRNA technology transfer will possess the necessary education and expertise. Through additional, specific training, they will be well-equipped to implement mRNA technology in the production of innovative medicines.
